公开(公告)号：EP2085468A1

公开(公告)日：2009-08-05

申请号：EP08019287.5

申请日：2001-04-27

申请人： ST. JUDE CHILDREN'S RESEARCH HOSPITAL

发明人： Hoffmann, Erich

IPC分类号： C12N7/04 ,  C12N15/85 ,  C12N15/44 ,  C07K14/11 ,  A61K39/145

CPC分类号： C07K14/005 ,  A61K2039/5252 ,  A61K2039/5254 ,  C12N7/00 ,  C12N2720/00063 ,  C12N2760/16122 ,  C12N2760/16151 ,  C12N2760/16163 ,  C12N2760/16222 ,  C12N2760/16263 ,  C12N2760/18663 ,  C12N2770/24263 ,  C12N2800/107 ,  C12N2800/40 ,  C12N2830/205 ,  C12N2830/34 ,  C12N2830/36 ,  C12N2830/85

摘要： The present invention is based on the development of a dual promoter system (preferably a RNA pol I -pol II system) for the efficient intracellular synthesis of viral RNA. The resultant minimal plasmid-based system may be used to synthesize any RNA virus, preferably viruses with a negative single stranded RNA genome. The viral product of the system is produced when the plasmids of the system are introduced into a suitable host cell. One application of the system is production of attenuated, reassortant influenza viruses for use as antigens in vaccines. The reassortant viruses generated by cotransfection of plasmids may comprise genes encoding the surface glycoproteins hemagglutinin and neuraminidase from an influenza virus currently infecting the population and the internal genes from an attenuated influenza virus. An advantageous property of the present invention is its versatility; the system may be quickly and easily adapted to synthesize an attenuated version of any RNA virus. Attenuated or inactivated RNA viruses produced by the present invention may be administered to a patient in need of vaccination by any of several routes including intranasally or intramuscularly.

摘要翻译： 本发明基于用于病毒RNA的有效细胞内合成的双重启动子系统（优选RNA pol I -pol II系统）的开发。 所得到的基于最小质粒的系统可用于合成任何RNA病毒，优选具有负单链RNA基因组的病毒。 当将系统的质粒引入合适的宿主细胞时，产生该系统的病毒产物。 该系统的一个应用是生产用作疫苗中抗原的减毒重配流感病毒。 通过共转染质粒产生的重配病毒可以包含编码来自目前感染群体的流感病毒的表面糖蛋白血凝素和神经氨酸酶的基因以及来自减毒流感病毒的内部基因。 本发明的有利特征是其多功能性; 该系统可以快速且容易地适应于合成任何RNA病毒的减毒版本。 本发明产生的减毒或灭活的RNA病毒可以通过包括鼻内或肌肉内的几种途径中的任何途径施用于需要接种疫苗的患者。

公开(公告)号：EP0672192A4

公开(公告)日：1996-04-17

申请号：EP93914329

申请日：1993-06-01

申请人： GLENN JEFFREY S

发明人： GLENN JEFFREY S

IPC分类号： C12N7/04 ,  A61K31/365 ,  A61K38/00 ,  A61K45/00 ,  A61P31/12 ,  C07K14/005 ,  C07K14/08 ,  C12N7/06 ,  C12Q1/02 ,  C12Q1/18 ,  C12Q1/68 ,  G01N33/15 ,  G01N33/50 ,  G01N33/569 ,  G01N33/576 ,  C12Q1/70 ,  A61K35/76

CPC分类号： G01N33/502 ,  A61K31/365 ,  A61K38/005 ,  C07K14/005 ,  C12N7/00 ,  C12N2770/24222 ,  C12N2770/24263 ,  C12Q1/18 ,  C12Q1/6897 ,  G01N33/5008 ,  G01N33/5097 ,  G01N33/56983 ,  G01N33/5765

摘要： PCT No. PCT/US93/05247 Sec. 371 Date Jun. 23, 1995 Sec. 102(e) Date Jun. 23, 1995 PCT Filed Jun. 1, 1993 PCT Pub. No. WO93/24660 PCT Pub. Date Dec. 9, 1993Viral morphogenesis, production, release or uncoating can be inhibited by effecting inhibition of prenylation of, or inhibition of post-prenylation reactions of, at least one viral protein. The use of inhibitors of prenylation, and post-prenylation reactions, for example, inhibitors of the mevalonate and prenyl group synthesis pathways, inhibitors of prenyl group transferases and mimics of the prenylation target CXXX box are disclosed.

公开(公告)号：EP2484378A4

公开(公告)日：2013-05-22

申请号：EP10820650

申请日：2010-09-30

申请人： TORAY INDUSTRIES ,  JP NAT INST OF INFECTIOUS DISEASES ,  TOKYO METROPOLITAN INST MEDICAL SCIENCE

发明人： WAKITA TAKAJI ,  MORIYAMA MASAKI ,  AKAZAWA DAISUKE ,  NAKAMURA NORIKO

IPC分类号： A61K39/29 ,  A61K9/16 ,  A61K39/39 ,  A61K47/02 ,  A61K47/34 ,  A61P1/16 ,  A61P31/12 ,  A61P37/04 ,  C07K14/18 ,  C07K19/00 ,  C12N7/04 ,  C12N15/09

CPC分类号： A61K39/29 ,  A61K39/12 ,  A61K2039/5252 ,  A61K2039/5258 ,  A61K2039/545 ,  A61K2039/55505 ,  A61K2039/55561 ,  A61K2039/57 ,  C07K2319/30 ,  C12N7/00 ,  C12N2770/24222 ,  C12N2770/24223 ,  C12N2770/24234 ,  C12N2770/24263

公开(公告)号：EP0948256A1

公开(公告)日：1999-10-13

申请号：EP97913882.0

申请日：1997-10-27

申请人： THE UNIVERSITY OF WASHINGTON

发明人： LOEB, Lawrence, A. ,  MULLINS, James, I.

IPC分类号： C12N15 ,  A61K31 ,  A61K39 ,  A61K45 ,  A61P31 ,  C07H19 ,  C12N5 ,  C12N7 ,  C12Q1

CPC分类号： A61K31/7076 ,  A61K31/7068 ,  A61K31/7072 ,  A61K31/708 ,  A61K45/06 ,  C12N7/00 ,  C12N15/102 ,  C12N2740/16063 ,  C12N2770/24161 ,  C12N2770/24261 ,  C12N2770/24263

摘要： The present invention is directed to the identification and use of ribonucleoside analogs to induce the mutation of an RNA virus, including HIV and HCV, or a virus which otherwise replicates through an RNA intermediate. The increase in the mutation rate of the virus results in reduced viability of progeny generations of the virus, thereby inhibiting viral replication. In addition to these methods and related compositions, the invention provides methods and combinatorial chemistry libraries for screening ribonucleoside analogs for mutagenic potential.

公开(公告)号：EP2213299A1

公开(公告)日：2010-08-04

申请号：EP09151596.5

申请日：2009-01-29

申请人： Vandevelde, Michel ,  Margery, Hélène

发明人： Vandevelde, Michel ,  Margery, Hélène

IPC分类号： A61K39/21 ,  A61K39/12

CPC分类号： C12N7/00 ,  A61K2039/5158 ,  A61K2039/5252 ,  C12N2740/16063 ,  C12N2760/10063 ,  C12N2760/14163 ,  C12N2770/24263

摘要： Procédé de préparation d'une composition, utilisation d'une composition et composition vaccinale à base d'au moins une souche de virus exhibant au moins une protéine à motif(s) en doigt de zinc PZ, comprenant ces virus dans un état inactivé dans lequel le zinc a été éjecté de ladite au moins une protéine PZ par une réaction d'oxydoréduction avec de l'azodicarbonamide, ces virus étant entiers et présentant une enveloppe virale intacte après inactivation, et de la biurée formée à partir de l'azodicarbonamide au cours de ladite réaction d'oxydoréduction, ainsi qu'éventuellement un reliquat d'azodicarbonamide n'ayant pas réagi.

摘要翻译： 疫苗组合物制成的至少一个病毒株参展具有锌指基序的至少一种蛋白质，包括：病毒，其中锌失活状态，其从蛋白质喷出用azodicarboxamides一种氧化还原反应，其中所述病毒是整套并且具有病毒 信封灭活后完好; 联二脲从氧化还原反应过程中azodicarboxamides形成的; 和任选未反应的azodicarboxamides残余物。 一个独立的claimsoft包括用于制备疫苗组合物，包括：使所述病毒株表现出与微粉化azodicarboxamides蛋白质; 通过保留信封完好无损贯通病毒的病毒包膜微粉azodicarboxamides; 和由微粉化azodicarboxamides并在从蛋白质的锌和偶氮二酰胺的局部分解成联二脲的喷射所得由蛋白质之间的氧化还原反应灭活病毒。 活动：杀病毒剂。 作用机制：疫苗。

公开(公告)号：EP1317559B1

公开(公告)日：2009-01-07

申请号：EP01932704.8

申请日：2001-04-27

申请人： ST. JUDE CHILDREN'S RESEARCH HOSPITAL

发明人： HOFFMANN, Erich

IPC分类号： C12N15/85 ,  C12N15/44 ,  C07K14/11 ,  A61K39/145 ,  C12N7/04

CPC分类号： C07K14/005 ,  A61K2039/5252 ,  A61K2039/5254 ,  C12N7/00 ,  C12N2720/00063 ,  C12N2760/16122 ,  C12N2760/16151 ,  C12N2760/16163 ,  C12N2760/16222 ,  C12N2760/16263 ,  C12N2760/18663 ,  C12N2770/24263 ,  C12N2800/107 ,  C12N2800/40 ,  C12N2830/205 ,  C12N2830/34 ,  C12N2830/36 ,  C12N2830/85

摘要： The present invention is based on the development of a dual promoter system (preferably a RNA pol I -pol II system) for the efficient intracellular synthesis of viral RNA. The resultant minimal plasmid-based system may be used to synthesize any RNA virus, preferably viruses with a negative single stranded RNA genome. The viral product of the system is produced when the plasmids of the system are introduced into a suitable host cell. One application of the system is production of attenuated, reassortant influenza viruses for use as antigens in vaccines. The reassortant viruses generated by cotransfection of plasmids may comprise genes encoding the surface glycoproteins hemagglutinin and neuraminidase from an influenza virus currently infecting the population and the internal genes from an attenuated influenza virus. An advantageous property of the present invention is its versatility; the system may be quickly and easily adapted to synthesize an attenuated version of any RNA virus. Attenuated or inactivated RNA viruses produced by the present invention may be administered to a patient in need of vaccination by any of several routes including intranasally or intramuscularly.

公开(公告)号：EP0111549A4

公开(公告)日：1985-02-28

申请号：EP83902213

申请日：1983-06-07

申请人： PURCELL ROBERT H ,  FEINSTONE STEPHEN M

发明人： PURCELL ROBERT H

IPC分类号： A01N29/00 ,  A61K20060101 ,  A61K31/02 ,  A61K35/14 ,  A61K35/16 ,  A61K38/37 ,  A61K39/12 ,  A61K39/285 ,  A61K39/29 ,  A61L2/00 ,  C12N7/06

CPC分类号： C12N7/00 ,  A61K31/14 ,  A61K35/16 ,  A61K38/37 ,  A61L2/0005 ,  A61L2/0088 ,  A61L2/18 ,  C12N2730/10163 ,  C12N2770/24263

摘要： A method of inactivating a lipid virus in a protein carrier selected from the group consisting of Hepatitis B virus (HBV) and non-A, non-B hepatitis (NANBH) by contacting said virus for an extended period of time and ambient temperature with a halohydrocarbon treating agent preferably chloroform in an amount of 5% v/v to 50% v/v.

摘要翻译： 一种通过将所述病毒延长一段时间和环境温度与一种乙型肝炎病毒（HBV）和非乙型非乙型肝炎（NANBH）的蛋白质载体中的脂质病毒灭活的方法， 卤代烃处理剂优选为5％v / v至50％v / v的氯仿。

公开(公告)号：EP2484378A1

公开(公告)日：2012-08-08

申请号：EP10820650.9

申请日：2010-09-30

申请人： Toray Industries, Inc. ,  Japan As Represented By Director-General Of National Institute Of Infectious Diseases ,  Tokyo Metropolitan Institute of Medical Science

发明人： WAKITA, Takaji ,  MORIYAMA, Masaki ,  AKAZAWA, Daisuke ,  NAKAMURA, Noriko

IPC分类号： A61K39/29 ,  A61K9/16 ,  A61K39/39 ,  A61K47/02 ,  A61K47/34 ,  A61P1/16 ,  A61P31/12 ,  A61P37/04 ,  C07K14/18 ,  C07K19/00 ,  C12N7/04 ,  C12N15/09

CPC分类号： A61K39/29 ,  A61K39/12 ,  A61K2039/5252 ,  A61K2039/5258 ,  A61K2039/545 ,  A61K2039/55505 ,  A61K2039/55561 ,  A61K2039/57 ,  C07K2319/30 ,  C12N7/00 ,  C12N2770/24222 ,  C12N2770/24223 ,  C12N2770/24234 ,  C12N2770/24263

摘要： A combination of an HCV antigen for inducing an antibody having the activity of inhibiting HCV infection and an optimum adjuvant is discovered, so as to provide an effective HCV vaccine composition. The hepatitis C virus vaccine composition comprises: inactivated viral particles obtained by inactivating infectious hepatitis C virus particles prepared from hepatitis C virus genome that contains sequences encoding NS3 protein, NS4A protein, NS4B protein, NS5A protein and NS5B protein derived from hepatitis C virus JFH1 strain;
an oligonucleotide containing unmethylated CpG, according to SEQ ID NO: 5 in the sequence listing; and
aluminium hydroxide.

摘要翻译： 发现用于诱导具有抑制HCV感染活性的抗体的HCV抗原与最佳佐剂的组合，以提供有效的HCV疫苗组合物。 丙型肝炎病毒疫苗组合物包含：灭活由丙型肝炎病毒基因组制备的感染性丙型肝炎病毒颗粒获得的灭活病毒颗粒，其含有编码NS3蛋白，NS4A蛋白，NS4B蛋白，NS5A蛋白和来源于丙型肝炎病毒JFH1菌株的NS5B蛋白的序列 ; 含有序列表中SEQ ID NO：5的未甲基化CpG的寡核苷酸; 和氢氧化铝。

公开(公告)号：EP1317559A2

公开(公告)日：2003-06-11

申请号：EP01932704.8

申请日：2001-04-27

申请人： ST. JUDE CHILDREN'S RESEARCH HOSPITAL

发明人： HOFFMANN, Erich

IPC分类号： C12N15/85 ,  C12N15/44 ,  C07K14/11 ,  A61K39/145 ,  C12N7/04

CPC分类号： C07K14/005 ,  A61K2039/5252 ,  A61K2039/5254 ,  C12N7/00 ,  C12N2720/00063 ,  C12N2760/16122 ,  C12N2760/16151 ,  C12N2760/16163 ,  C12N2760/16222 ,  C12N2760/16263 ,  C12N2760/18663 ,  C12N2770/24263 ,  C12N2800/107 ,  C12N2800/40 ,  C12N2830/205 ,  C12N2830/34 ,  C12N2830/36 ,  C12N2830/85

摘要： The present invention is based on the development of a dual promoter system (preferably a RNA pol I -pol II system) for the efficient intracellular synthesis of viral RNA. The resultant minimal plasmid-based system may be used to synthesize any RNA virus, preferably viruses with a negative single stranded RNA genome. The viral product of the system is produced when the plasmids of the system are introduced into a suitable host cell. One application of the system is production of attenuated, reassortant influenza viruses for use as antigens in vaccines. The reassortant viruses generated by cotransfection of plasmids may comprise genes encoding the surface glycoproteins hemagglutinin and neuraminidase from an influenza virus currently infecting the population and the internal genes from an attenuated influenza virus. An advantageous property of the present invention is its versatility; the system may be quickly and easily adapted to synthesize an attenuated version of any RNA virus. Attenuated or inactivated RNA viruses produced by the present invention may be administered to a patient in need of vaccination by any of several routes including intranasally or intramuscularly.

公开(公告)号：EP0672192B1

公开(公告)日：1999-10-13

申请号：EP93914329.3

申请日：1993-06-01

申请人： Glenn, Jeffrey S.

发明人： Glenn, Jeffrey S.

IPC分类号： A61K35/76 ,  C12N7/04 ,  C12N7/06 ,  G01N33/50 ,  C12Q1/70

CPC分类号： G01N33/502 ,  A61K31/365 ,  A61K38/005 ,  C07K14/005 ,  C12N7/00 ,  C12N2770/24222 ,  C12N2770/24263 ,  C12Q1/18 ,  C12Q1/6897 ,  G01N33/5008 ,  G01N33/5097 ,  G01N33/56983 ,  G01N33/5765 ,  Y02A50/463 ,  Y02A50/54

摘要： PCT No. PCT/US93/05247 Sec. 371 Date Jun. 23, 1995 Sec. 102(e) Date Jun. 23, 1995 PCT Filed Jun. 1, 1993 PCT Pub. No. WO93/24660 PCT Pub. Date Dec. 9, 1993Viral morphogenesis, production, release or uncoating can be inhibited by effecting inhibition of prenylation of, or inhibition of post-prenylation reactions of, at least one viral protein. The use of inhibitors of prenylation, and post-prenylation reactions, for example, inhibitors of the mevalonate and prenyl group synthesis pathways, inhibitors of prenyl group transferases and mimics of the prenylation target CXXX box are disclosed.